Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,261 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,261 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus… | Phase 2 | terminated | Oct 9, 2020 | GlaxoSmithKline | Trial terminated by GSK for strategic reasons, after all participants completed treatment. This… | Safety / toxicity |
| NCT06676917 | Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With…(TUXEDO-5) | Phase 2 | withdrawn | Nov 6, 2024 | MedSIR | The clinical trial has not been approved by the regulatory authority. | Other (stated, no rule matched) |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by… | Phase 2 | withdrawn | Jun 26, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT05420636 | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary… | Phase 2 | terminated | Jun 15, 2022 | Fox Chase Cancer Center | Closed to accrual due to low probability of successful outcomes | Enrollment / accrual |
| NCT05617313 | Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell… | Phase 2 | terminated | Nov 15, 2022 | Jeffrey Clarke | Study did not meet the criteria for continuation after interim analysis | Efficacy / futility |
| NCT05691829 | Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV…(IRRADIATE-Lung) | Phase 2 | terminated | Jan 20, 2023 | NYU Langone Health | Terminated due to insufficient enrollment. | Enrollment / accrual |
| NCT04615884 | Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients(CH:II) | N/A | withdrawn | Nov 4, 2020 | Lady Davis Institute | unable to secure the funding despite multiple grant applications | Funding |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT03087708 | Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | Phase 2 | terminated | Mar 22, 2017 | Alliance for Clinical Trials in Oncology | Insufficient accrual | Enrollment / accrual |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05788926 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer… | Phase 1 | terminated | Mar 29, 2023 | Transgene | Sponsor decision not related to safety | Safety / toxicity |
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | — | terminated | Nov 14, 2012 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT03777124 | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus… | Phase 2 | terminated | Dec 17, 2018 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | Phase 1 | terminated | Oct 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT04921358 | Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or… | Phase 3 | terminated | Jun 10, 2021 | BeiGene | Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to… | Safety / toxicity |
| NCT06643117 | Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as…(Lotus) | Phase 3 | terminated | Oct 16, 2024 | Formycon AG | Formycon concluded that continuing the trial is no longer necessary for the development and… | Other (stated, no rule matched) |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT05251805 | The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery | N/A | terminated | Feb 23, 2022 | Universitair Ziekenhuis Brussel | Initial observations suggest challenges in performing bone marrow aspiration in the first few… | Enrollment / accrual |
| NCT04820023 | Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment | Phase 1 / Phase 2 | terminated | Mar 29, 2021 | Bridge Biotherapeutics, Inc. | Sponsor's decision considering the changing treatment landscape for NSCLC | Sponsor / business decision |
| NCT06140407 | Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung… | Phase 2 | terminated | Nov 20, 2023 | Vanderbilt-Ingram Cancer Center | Low accrual and Merck discontinuing funding and drug supply | Drug supply |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | — | withdrawn | Jul 10, 2024 | Mayo Clinic | Resident working with study left institution | Other (stated, no rule matched) |
| NCT03505710 | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated…(DESTINY-Lung01) | Phase 2 | terminated | Apr 23, 2018 | Daiichi Sankyo | Last participant transitioned to alternative study. | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT04441138 | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III…(ESR1814205) | Phase 2 | terminated | Jun 22, 2020 | Rush University Medical Center | Institutional constraints due to research staffing and diminished data safety monitoring… | Safety / toxicity |
| NCT05840770 | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small… | Phase 2 | withdrawn | May 3, 2023 | City of Hope Medical Center | no accrual | Enrollment / accrual |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT02093962 | Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous… | Phase 2 | terminated | Mar 21, 2014 | ImmunoGenesis | At the interim analysis, the futility boundary was not met and the study was stopped due to… | Efficacy / futility |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated…(GeoMETry-III) | Phase 3 | terminated | Jun 11, 2020 | Novartis Pharmaceuticals | Company decision not related to any safety concerns. | Safety / toxicity |
| NCT03877250 | Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies | — | withdrawn | Mar 15, 2019 | Memorial Sloan Kettering Cancer Center | The primary objectives have not been met due to no patient enrollment therefore, the PI is… | Enrollment / accrual |
| NCT02521051 | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic… | Phase 1 / Phase 2 | terminated | Aug 13, 2015 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT05374538 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant… | Phase 1 | terminated | May 16, 2022 | Vitrac Therapeutics, LLC | Sponsor decision | Sponsor / business decision |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients… | Phase 1 | terminated | Mar 7, 2023 | Coherus Oncology, Inc. | The study was terminated for strategic reasons (not for safety concerns) | Safety / toxicity |
| NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and… | Phase 1 | terminated | May 3, 2023 | Mirati Therapeutics Inc. | Business objectives have changed | Sponsor / business decision |
| NCT05275673 | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous… | Phase 2 | terminated | Mar 11, 2022 | Faeth Therapeutics | Sponsor decision - funding issues | Funding |
| NCT06522360 | Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced… | Phase 2 | withdrawn | Jul 26, 2024 | M.D. Anderson Cancer Center | 0 participants enrolled | Enrollment / accrual |
| NCT04892472 | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields…(KEYNOTE B36) | Phase 2 | terminated | May 19, 2021 | NovoCure GmbH | Phase 2 study terminated due to insufficient enrollment and was not based on safety concerns.… | Safety / toxicity |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 6, 2021 | NextCure, Inc. | Due to the limited activity in Phase 1, NextCure decided to discontinue development of the… | Other (stated, no rule matched) |
| NCT05790460 | Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients…(TESTING) | N/A | terminated | Mar 30, 2023 | Abramson Cancer Center at Penn Medicine | Insufficient accrual | Enrollment / accrual |
| NCT04485026 | Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma | Phase 2 | withdrawn | Jul 24, 2020 | Wake Forest University Health Sciences | No enrollments, low patient population as well as a dramatic change in the insurance approval… | Enrollment / accrual |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer…(SCope-D1) | Phase 1 | terminated | May 3, 2021 | AstraZeneca | AstraZeneca has decided to stop further enrollment and the study was terminated when all patients… | Safety / toxicity |
| NCT04925986 | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+… | Phase 2 | terminated | Jun 14, 2021 | Sarah Goldberg | Sponsor decision based on data from other clinical trials | Sponsor / business decision |
| NCT06094296 | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With… | Phase 2 | terminated | Oct 23, 2023 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Phase 1 | terminated | Nov 28, 2016 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 8, 2025source: clinicaltrials